Dermipsor's pipeline

Dermipsor is focused on the development of novel, synergistic combination therapies for dermatological diseases. Dermipsor has two clinical-stage drug candidates: DPS-101 for the treatment of plaque psoriasis, which completed a Phase 2b trial and is scheduled to start Phase 3 trials in the near future, and DPS-102 for the treatment of scalp psoriasis, which is scheduled to begin Phase 2 clinical studies in 2011. Additional programs are in preclinical stages.